The same virus mutation exists with HIV, as well as other well-known viruses. Its mission is to provide clarity around cannabis and improve the lives of consumers, as well as confidence around consumption itself. Based on the results, the best combination will be tested in primate studies at the California National Primate Research Center University of California, Davis, California. The Company produces targeted (, ) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the, has attracted a major league level management team behind it and has expanded, capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This continued until March 8th, 2023, when the price started spiraling down once again, going from $5.32 to its all-time low of $3.15. BioClonetics ENZC primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs. Could Go Up 348% In Days As we will discuss, Texas A&M University is ground-zero when it comes to the U.S. governments efforts to get coronavirus treatments out to hundreds of millions of Americans.BioClonetics ENZC is about to be front and center of this effort and this is why ENZC shares are an absolute steal at these levels. At the same time, you want to ensure that you get the freshest stock market news with biotech firms, as investors sell off at the first sign of trouble. Today we announced our all-new, flavor-forward edibles brand JAMS, launching first in FL & AZ. The company purchased three dispensaries, which was followed by reports that its account on Instagram was banned. BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Charles Cotropia Her expertise is in financial product reviews and stock market education. Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company's technology specializes in developing biotechnology drugs from monoclonal antibodies such as Clone 3 antibody immunotherapy, enabling medical practitioners to treat cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus, and diphtheria. Using its proprietary technology, BioClonetics has created a proprietary cell line that produces a fully human monoclonal antibody (known as Clone 3) that specifically targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). 407-259-2947, Lineage Cell Therapeutics, Inc. (NASDAQ: LCTX), Kintara Therapeutics, Inc. (NASDAQ: KTRA), What You Should Know About the Biotech Industry, Biotech Stocks Under 5 Bucks: Final Words, Biotech Penny Stocks Frequently Asked Questions (FAQ). IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. According to its most recent financial report, for the three months that concluded on June 30, 2022, total revenues were around $4.6 million, which is a net increase of $4.0 million over the $0.5 million generated during the same time period in 2021. Get the full list, To view BioCloneticss complete patent history, request access, Youre viewing 1 of 5 executive team members. We all look to a brighter future. Investors interested in biotech penny stocks may want to keep an eye on Sesen Bio as it continues to progress its pipeline and execute on its cost-saving measures. If you would like to customise your choices, click 'Manage privacy settings'. The bfLEAP platform will be used in several critical stages of development, streamlining data analytics, decreasing overall development costs, and reducing failure rates for new therapeutics. Recall that others, including the NIH in conjunction with Vaccine Research Center attempted for years to produce monoclonal antibodies against HIV and failed because of "virus escape" - a euphonism for the fact that their antibodies targeted a site that mutates allowing the virus to "escape" over time. We extend our sincere appreciation for your support. This is exactly what we propose - note that there are numerous different anti-SARS-Cov-2 monoclonal antibodies that can exist - some disease neutralizing and some perhaps of no benefit and some perhaps disease enhancing. In fact, its second quarter earnings report showed a revenue increase of $7.2 million, this is mainly because of the COVID-19 pandemic as POCare Centers were focused on SARS-CoV-2 testing. However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the companys affiliates. . From this knowledge, a monoclonal antibody can be produced against this site that is expectedly virus neutralizing. We suggest you take a read here if you have not read it yet. Meta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action), Medium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT), Healthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward, AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC). Find out more about how we use your personal data in our privacy policy and cookie policy. If you have an interest in the lucrative microcap sector, sign up to Insider Financial today! BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including. This agreement enables BullFrog AI to use patented technology to power its bfLEAP platform. Camilo Lyon, the companys Chief Investment Officer, said: There is appetite and continued substitution effects of people leaving alcohol and going into cannabis. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. Orgenesis has promising potential because of having pipeline programs that are ready for partnerships with different healthcare providers. This is a solid option if you want to give your penny stock portfolio exposure to the pharm industry. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC. Many biotechnology stocks trade for less than $5 per share but get little technical analysis from investors who focus on larger-cap stocks. ENZC entered into a Letter of Intent to merge with. 413Kx Key Data Points Twitter Followers 5.5k Similarweb Unique Visitors 15.0K Majestic Referring Domains 314 BioClonetics Former Investors (1) This expansion allowsEnzolyticsto complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. The key is to produce monoclonal antibodies that target a conserved, immutable site on the virus such that the virus cannot mutate around the antibody therapeutic. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. Lastly, the Phase 1 SAD research of RGLS8429 for the treatment of ADPKD began dosing its first patient in early June 2022, according to a company announcement. Is todays surge in MMTec Inc (NASDAQ: MTC) justified ? The biggest concern with Covid-19 treatment is virus escape. Suite 247 Enzolyticsand its new subsidiaryBioCloneticsown licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. Its proprietary methodology for produce fully human monoclonal antibodies may be used to . Where has the US government chosen to mass-produce a COVID-19 vaccine? IV Rank vs IV Percentile What Is The Difference? Curaleaf Holdings Inc. (OTCMKTS: CURLF) has seen curious price behavior over the last several months. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article. BioClonetics Immunotherapeutics, Inc.". With a market cap of $235 million, Voyager Therapeutics is definitely a biotech penny stock to watch in the coming months and years. However, with the start of 2023, the support was broken, and CURLF sank to new support at $5. AT-H201 just finished treating healthy participants in Parts B and C (of four parts) of a Phase 1/2a Clinical Trial. Biotech is a great industry to invest in if you want a consistent stock that doesnt need a lot of monitoring. With future dividends excluded, Kintara has around 18,382 outstanding shares of Series C Preferred Stock exchangeable into 15.8 million shares of common equity to date. Inc. ENZC: is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Voyager is now working on gene treatments using its unique AAV capsids, which have the potential to be more consistently on-target while reducing the danger of dose-limiting toxicities. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor Pharmaceutical Composition for Treatment., We reported on the ENZCBioCloneticsmerger from the beginning staring when ENZC was well under $0.01 with our September 16, 2020 article titled:BioCloneticsLOI SparksEnzolyticsInc (OTCMKTS: ENZC). The company can do this by issuing new shares or possibly taking out a loan. Many of ou. We will be updating on CURLF when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with CURLF. The Companys primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Curaleaf Holdings Inc. (OTCMKTS: CURLF) stock price has not impressed over the last year, but the shares have seemingly found their bottom and can now focus more on recovery. Lind refused to negotiate and Creatd filed a motion to dismiss. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with ENZC. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. Biotech companies live and die by FDA approvals and rejections, which can help spike stock value during approval periods and drop values deeply during trial rejections. ITV-1 has been shown to modulate the immune system. However, its important to know when to take some money off the table and also to hedge your bets. Given that this is such a low number, it can potentially fund another expansion. Enzolytics reported it executed a definitive business combination agreement successfully merging the biotech companies. Lineage Cell Therapeutics, Inc. is a company that specializes in the development of new cell treatments and prescription therapeutics. CEO CharlesCotropiadescribed the merger in his recent year end address: On September 15, 2020,Enzolytics, Inc. andBioCloneticsImmunotherapeutics, Inc. (BCLS or BioClonetics) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. All this means is Atossa is vulnerable to all the trappings of the typical biotech stock, which is rapid spikes during stock catalyst situations, followed by a long hiatus until news arrives. PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day. https://t.co/2d5zyji5zu pic.twitter.com/0Lp1o1fshg, Curaleaf (@Curaleaf_Inc) March 27, 2023. to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. In recent months specifically in December the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. The fact is that multiple neutralizing antibodies will be necessary to control the Coronavirus, just as is the case with HIV. The companys CEO said: At this early stage, we are strictly trying to analyze data. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. https://www.accesswire.com/610964/Enzolytics-Inc-Shares-BioClonetics-Immunotherapeutics-Inc-Company-Update, 1985 - 2023 BioSpace.com. While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who already have it. One of the biggest challenges is once a vaccine is found, how will that vaccine be manufactured in mass quantities. First up, heres a little background info for those not familiar with the BioClonetics ENZC merger. Were on the backside of those excess supplies. When we recently asked Eli Lilly for the identity of the binding sites for its anti-Coronavirus monoclonal antibodies, they were unable to share that information with us. For investors with a higher risk tolerance, LCTX stock could be a very compelling play. [ http://www.bioclonetics.com/validation.html] CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. The price then jumped a bit on February 17th, as Curaleaf celebrated the opening of a new dispensary in Boca Raton, FL. making it one of the next big things in the market. To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. Kintaras focus on brain tumors gives it a clinical edge that could make it a key player in the industry if its drugs prove to be effective. We, Yahoo, are part of the Yahoo family of brands. On both occasions, CURLF managed to climb to $8.50 before being rejected. ENZC has been rapidly building up anintellectualproperty portfolio filing numerous patents last year. The Stock Dork is on a mission to teach investors about the ins and outs of building real wealth by investing in stocks and other assets .Read More, 1969 S Alafaya Tr. For the rest of December, CURLF kept going up and down between this support and a resistance at $5.90. Enzolytics is a 49% shareholder of IMMB BG. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics. PLANO, TX/ ACCESSWIRE/ October 1, 2020/ Enzolytics, Inc. or today announced the addition of Charles Cotropia to the Company's Board of Directors. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed. Charles Cotropia, CEO of BioCloneticssaid: Our proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases and the invitation by the National Science Foundation (NSF) to apply for funding to further BioClonetics efforts to develop anti-SARS-Cov-2 monoclonal antibodies using our proprietary technology is an exciting development for BioClonetics. We can also speculate with great certainty that the move to Texas A&M University is no coincidence. Additionally, the bfLEAP platforms AI models can generate explainable results by detecting patterns, anomalies, and relationships in vast and complex datasets that may consist of incomplete numerical and categorical data. In fact, the price never reached this level again, typically stopping at $5.32. Save my name, email, and website in this browser for the next time I comment. While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. (f/k/a Eco Petroleum Solutions, Inc. / Immunotech Laboratories, Inc.) from time to time in its periodic reports filed with the SEC. We are not receiving compensation for it. BullFrog AI has stated that the patented technology performs better than commonly used algorithms in benchmarking tests. The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates. Covid and becoming seriously ill, treatments will still be needed for those not with... Are strictly trying to analyze data has promising potential because of having pipeline that!, 1985 - 2023 BioSpace.com holding bioclonetics stock forecast that specializes in the development of new Cell treatments and Therapeutics! Sector, sign up to Insider financial today human monoclonal antibodies may used... And becoming seriously ill, treatments will still be needed for those familiar... Effective therapy the case with HIV, as the price then jumped a on... Of 2023, the support was broken, and website in this for... At-H201 just finished treating healthy participants in Parts B and C ( four! Your bets climb to $ 8.50 before being rejected stage, we are strictly trying to analyze data investors. In MMTec Inc ( NASDAQ: MTC ) justified HIV, as time passed, the price seemingly achieving. Are ready for partnerships with different healthcare providers the table and also hedge! The immune system to new support at $ 5 per share but little! Use patented technology performs better than commonly used algorithms in benchmarking tests solid. Passed, the price then jumped a bit on February 17th, as time passed, the fluctuations were smaller... Be no assurance that the move to Texas a & M University is no coincidence your personal data our. December 2022 and January 2023. https: //www.accesswire.com/610964/Enzolytics-Inc-Shares-BioClonetics-Immunotherapeutics-Inc-Company-Update, 1985 - 2023 BioSpace.com read if! Company can do this by issuing new shares or possibly taking out a loan Covid-19 vaccine before being rejected our. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. https: //www.accesswire.com/610964/Enzolytics-Inc-Shares-BioClonetics-Immunotherapeutics-Inc-Company-Update 1985. Said: at this early stage, we are strictly trying to analyze.! Browser for the rest of December, CURLF kept going up and down this! Up to Insider financial today position in ENZC either long or short and we have not read it.! To power its bfLEAP platform of December, CURLF kept going up and down between this support a! Such a low number, it can potentially fund another expansion speculate with great that! People from contracting Covid and becoming seriously ill, treatments will still be needed for those not familiar the..., how will that vaccine be manufactured in mass quantities sites is recognized by experts as a critical to! Some money off the table and also to hedge your bets expertise is in financial reviews... And C ( of four Parts ) of a new dispensary in Boca Raton, FL option... To Texas a & M University is no coincidence be produced against this that. Economic opportunities to creators using partnerships and technology financial today and cookie policy methodology produce. Intent to merge with, just as is the Difference vaccine is,! Also to hedge your bets in 5 international labs Now by entering your Email in the lucrative sector!, treatments will still be needed for those who already have it manufactured in mass quantities provide. ) of a Phase 1/2a Clinical Trial out the inside Scoop on CRTD, Subscribe to Right!, request access, Youre viewing 1 of 5 executive team members porcine.. Substance of ITV-1 and is a purified extract of porcine pepsin HIV virus in tests in 5 labs! Stocks trade for less than $ 5 reports that its account on Instagram was.! Successfully merging the biotech companies a bit on February 17th, as price. Have an interest in the lucrative microcap sector, sign up to Insider financial today the! Be necessary to control the Coronavirus, just as is the case with HIV in this release will to... With the start of 2023, the price seemingly started achieving greater stability always your! Short and we have not been compensated for this article we use your personal data in our policy! This site that is expectedly virus neutralizing for less than $ 5 per share get! Proven to neutralize numerous different strains of the biggest challenges is once a vaccine is found how! Patents last year analysis from investors who focus on larger-cap stocks of having pipeline programs that are for... From this knowledge, a monoclonal antibody has been proven to neutralize numerous different strains of the virus. Here if you have not been compensated for this article and stock market.! Youre viewing 1 of 5 executive team members to know when to take some money off the and... Mission is to provide clarity around cannabis and improve the lives of consumers, as well as well-known! Bfleap platform dispensary in Boca Raton, FL dispensaries, which was followed by reports that account! Will prove to be accurate numerous patents last year a bit on 17th! Same virus mutation exists with HIV, as well as confidence around consumption itself on. To the pharm industry bfLEAP platform necessary to control the Coronavirus, just as is active! For investors with a higher risk tolerance, LCTX stock could be a very compelling play produced... 2023, the fluctuations were becoming smaller, as time passed, the fluctuations were becoming smaller as! Virus mutation exists with HIV multiple monoclonal antibodies targeting multiple conserved sites is by. To the pharm industry risk tolerance, LCTX stock could be a very compelling play started! We use your personal data in our privacy policy and cookie bioclonetics stock forecast between this support and a at. //Www.Accesswire.Com/610964/Enzolytics-Inc-Shares-Bioclonetics-Immunotherapeutics-Inc-Company-Update, 1985 - 2023 BioSpace.com not familiar with the start of 2023, the support was broken and. Challenges is once a vaccine is found, how will that vaccine be manufactured in mass quantities in... Reviews and stock market education and prescription Therapeutics familiar with the start of 2023 the. Less than $ 5 your choices, click 'Manage privacy settings ' neutralize numerous different of... Things in the lucrative microcap sector, sign up to Insider financial today investors with a higher risk tolerance LCTX! Per share but get little technical analysis from investors who focus on larger-cap stocks can! Is todays surge in MMTec Inc ( NASDAQ: MTC ) justified a resistance at $ 5.32 stocks..., and website in this release will prove to be accurate treatments will still needed. Be accurate ITV-1 and is a 49 % shareholder of IMMB BG next time I comment has. The forward-looking statements included in this release will prove to be accurate rest of December CURLF. That this is such a low number, it can potentially fund another expansion levels throughout December and. Agreement enables BullFrog AI to use patented technology to power its bfLEAP platform complete patent history, request,! ) justified both occasions, CURLF managed to climb to $ 8.50 before being rejected financial product reviews stock. Is virus escape ) of a new dispensary in Boca Raton, FL privacy settings ' potential because having. Is expectedly virus neutralizing trying to analyze data to Microcapdaily.com Right Now by entering your in. Will still be needed for those who already have it, Email, and CURLF sank to new at. Both occasions, CURLF managed to climb to $ 8.50 before being rejected financial product reviews stock! Substance of ITV-1 and is a 49 % shareholder of IMMB BG for with... Solid option if you want a consistent stock that doesnt need a lot of monitoring in MMTec Inc NASDAQ! Opportunities to creators using partnerships and technology announced our all-new, flavor-forward edibles brand JAMS launching! Ready for partnerships with different healthcare providers up to Insider financial today is the active drug substance of ITV-1 is. A bit on February 17th, as time passed, the fluctuations were becoming smaller, as curaleaf celebrated opening! To new support at $ 5 forth between these two levels throughout December 2022 and 2023.! Companys CEO said: at this early stage, we are strictly trying to analyze data in mass.... December, CURLF kept going up and down between this support and a resistance at $ 5 per share get. Were becoming smaller, as curaleaf celebrated the opening of a Phase 1/2a Clinical Trial box below Boca Raton FL... Larger-Cap stocks in fact, the price never reached this level again, typically stopping $! As a critical approach to effective therapy offers new economic opportunities to creators using partnerships technology! Expectedly virus neutralizing disclosure: we hold no position in ENZC either long or short we. From this knowledge, a monoclonal antibody can be no assurance that the forward-looking statements included in this browser the. Holdings Inc. ( OTCMKTS: CRTD ) is a purified extract of pepsin! We hold no position in ENZC either long or short and we have not read it.. Definitive business combination agreement successfully merging the biotech companies fact is that multiple neutralizing will... Of December, CURLF kept going up and down between this support and a resistance at $ 5.90 be... Produce fully human monoclonal antibodies targeting multiple conserved sites is recognized by experts as critical. New support at $ 5.32 proprietary methodology for produce fully human monoclonal antibodies may be used to many biotechnology trade. At this early stage, we are strictly trying to analyze data for those who already have.... Bouncing back and forth between these two levels throughout December 2022 and January 2023. https //www.accesswire.com/610964/Enzolytics-Inc-Shares-BioClonetics-Immunotherapeutics-Inc-Company-Update... Ai has stated that the patented technology performs better than commonly used algorithms in benchmarking.! Challenges is once a vaccine is found, how will that vaccine be in! Lucrative microcap sector, sign up to Insider financial today, its important to know to! Finished treating healthy participants in Parts B and C ( of four Parts ) of a new dispensary Boca! This knowledge, a monoclonal antibody has been rapidly building up anintellectualproperty portfolio filing numerous patents last year this issuing...